Indaptus Therapeutics, Inc.
$3.61
▼
-5.88%
2026-04-21 07:31:00
indaptusrx.com
NCM: INDP
Explore Indaptus Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.74 M
Current Price
$3.61
52W High / Low
$19.91 / $1.51
Stock P/E
—
Book Value
$1.45
Dividend Yield
—
ROCE
-629.32%
ROE
-5.88%
Face Value
—
EPS
$-21.58
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
0.99
Debt / Equity
0
Current Ratio
1.51
Quick Ratio
1.51
Forward P/E
-1.52
Price / Sales
—
Enterprise Value
$-3.77 M
EV / EBITDA
0.19
EV / Revenue
—
Rating
None
Target Price
$10
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 2. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 3. | Marker Therapeutics, Inc. | $1.67 | — | $27.84 M | — | -74.05% | -68.81% | $4.07 / $0.81 | $1.01 |
| 4. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
| 5. | Lexicon Pharmaceuticals, Inc. | $1.84 | — | $764.74 M | — | -29.8% | -39.72% | $1.95 / $0.49 | $0.3 |
| 6. | Oramed Pharmaceuticals Inc. | $3.83 | 3.45 | $151.27 M | 0% | -7.12% | 37.1% | $3.96 / $1.98 | $4.98 |
| 7. | PepGen Inc. | $1.73 | — | $117.5 M | — | -58.05% | -67.39% | $7.8 / $1.01 | $2.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -8.16 M | -2.65 M | -4.46 M | -4.57 M | -4.17 M | — |
| Net Profit | -8.11 M | -2.98 M | -5.23 M | -4.53 M | -4.13 M | — |
| EPS in Rs | -3.62 | -1.33 | -2.33 | -2.02 | -1.84 | -9.04 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -19.83 M | -15.37 M | -16.38 M | -14.91 M |
| Net Profit | -20.85 M | -15.02 M | -15.42 M | -14.32 M |
| EPS in Rs | -9.3 | -6.7 | -6.88 | -6.39 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.31 M | 7.34 M | 14.92 M | 28.06 M |
| Total Liabilities | 6.16 M | 3.39 M | 2.85 M | 3.43 M |
| Equity | 3.15 M | 3.94 M | 12.08 M | 24.63 M |
| Current Assets | 9.31 M | 6.62 M | 14 M | 27.24 M |
| Current Liabilities | 6.16 M | 3.39 M | 2.77 M | 3.43 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -14.82 M | -12.32 M | -13.41 M | -13.08 M |
| Investing CF | — | 0 M | 17.14 M | -16.43 M |
| Financing CF | 17.54 M | 4.75 M | 0 M | 0 M |
| Free CF | -14.82 M | -12.32 M | -13.41 M | -13.08 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 2.6% | -7.68% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-27 | 1:0.0357143 |
| 2021-07-27 | 1:0.25 |